Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Effects of fish oil supplementation on eicosanoid production in patients at higher risk for colorectal cancer

White, Maya N.a; Shrubsole, Martha J.a,b,c,e; Cai, Qiuyina,b,c; Su, Timothya,b,c; Hardee, Jenningsh; Coppola, John-Anthonyi; Cai, Sunny S.j; Martin, Stephanie M.a,d; Motley, Sandraa,b; Swift, Larry L.f; Milne, Ginger L.g; Zheng, Weia,b,c,e; Dai, Qia,b,c; Murff, Harvey J.a,d,e

European Journal of Cancer Prevention: May 2019 - Volume 28 - Issue 3 - p 188–195
doi: 10.1097/CEJ.0000000000000455
Research Papers: Gastrointestinal Cancer
Buy

Fish oil supplementation may represent a potential chemopreventive agent for reducing colorectal cancer risk. The mechanism of action of fish oil is unknown but presumed to be related to eicosanoid modification. The purpose of this study was to evaluate the effects of fish oil supplementation on the levels of urinary and rectal eicosanoids. We conducted a randomized, double-blind, controlled trial of 2.5 g of fish oil per day compared with olive oil supplementation over a 6-month period. Study participants had a history of colorectal adenomas. Randomization was stratified based on the gene variant rs174535 in the fatty acid desaturase 1 enzyme (FADS1), which affects tissue levels of arachidonic acid. A total of 141 participants were randomized. Urinary prostaglandin E2 metabolite (PGE-M) was measured at baseline, 3, and 6 months and rectal prostaglandin E2 (PGE2) at baseline and 6 months. Repeated-measures linear regression was used to determine the effect of the intervention on each outcome measure. Overall, fish oil supplementation was found to reduce urinary PGE-M production compared with olive oil (P=0.03). Fish oil did not reduce rectal PGE2 overall; however, it did significantly reduce PGE2 in the subgroup of participants not using aspirin or NSAIDs (P=0.04). FADS1 genotype did not seem to modify effects of fish oil on PGE2 production. We conclude that fish oil supplementation has a modest but beneficial effect on eicosanoids associated with colorectal carcinogenesis, particularly in those not taking aspirin or NSAIDs.

aDepartment of Medicine

bDivision of Epidemiology

cVanderbilt Ingram Cancer Center

dDivision of General Internal Medicine and Public Health, Vanderbilt University Medical Center

eGRECC, Department of Veterans Affairs, Tennessee Valley Healthcare System

fDepartment of Pathology, Microbiology and Immunology, Vanderbilt University

gDivision of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville

hUniversity of Tennessee, Knoxville, Tennessee

iUniversity of Florida College of Medicine, Gainesville, Florida

jTulane University School of Medicine, New Orleans, Louisiana, USA

Correspondence to Harvey J. Murff, MD, MPH, Division of General Internal Medicine and Public Health, Vanderbilt University, 6012 Medical Center East, 1215 21st Avenue South, Nashville, Tennessee 37232, USA Tel: +1 372 328 300; fax: +1 615 936 1269; e-mail: harvey.j.murff@vanderbilt.edu

Received October 3, 2017

Accepted February 23, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.